Leerink Partners analyst Whit Mayo has reiterated their bullish stance on AHCO stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Whit Mayo has given his Buy rating due to a combination of factors that highlight AdaptHealth’s strategic positioning and financial performance. Despite a slight decline in revenue compared to estimates, the company achieved a notable EBITDA beat, surpassing consensus expectations by nearly 3%. This strong EBITDA performance, alongside a sequential improvement in EBITDA margin, underscores the company’s operational efficiency.
Additionally, AdaptHealth’s strategic divestiture of non-core assets, such as the sale of its incontinence and infusion assets, aligns with its focus on core business areas, potentially enhancing long-term growth prospects. Although the company lowered its 2025 revenue and EBITDA guidance, these adjustments appear to account for the recent asset sales, suggesting a more streamlined and focused business model. Overall, these factors contribute to Whit Mayo’s positive outlook on AdaptHealth’s stock.
In another report released today, UBS also maintained a Buy rating on the stock with a $15.00 price target.